Inozyme Pharma Current Cash

Inozyme Pharma posts a current cash of $26M as of March 2025. That compares with $21M in the prior-year period — up 25.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Inozyme Pharma's current cash was $21M. The latest reading is $26M — a 25.4% year-over-year increase (period ending March 2025). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of Inozyme Pharma's financial statement story. At $26M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for INZY's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Inozyme Pharma's other metric pages and overview cover the third.

Judging Inozyme Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current cash easier to interpret. Start with $26M here, then scan peer and history charts to see if the gap is persistent.